Table II. Immunology of NZB/W F1 mice with established lupus nephritis treated with irinotecan compared with saline-treated controls.
Treatment from Proteinuria Grade 3+ (Time to Sacrifice after Completion of the Treatment)
1 wk after Saline1 wk after Irinotecan4 wk after Irinotecan
Spleen cell populations
  B220+ cells (%)32.19 ± 7.3424.04 ± 5.2031.78 ± 6.81
  IgMlowIgDlow B cells (%)20.59 ± 5.9413.67 ± 2.52*23.68 ± 3.77
  IgG-producing B cells (ELISPOTs per 106 cells)12011 ± 59521387 ± 1120**11093 ± 1577
  CD4+/CD8+ ratio5.91 ± 2.983.92 ± 1.346.16 ± 1.88
  CD69+ CD4 cells (%)5.79 ± 3.284.63 ± 1.529.66 ± 1.95*
Neutrophils from peripheral blood (103/mm3)0.33 ± 0.120.65 ± 0.720.33 ± 0.15
IgG anti-ds DNA (A405–490 nm)2.17 ± 0.631.68 ± 0.902.37 ± 0.50
Total IgG (mg/ml)11.72 ± 8.228.62 ± 5.6225.78 ± 10.60*
  • Two groups of NZB/W F1 mice were treated from grade 3+ proteinuria with irinotecan (50 mg/kg, a total of six applications within 2 wk) or saline (10 ml/kg), and sacrificed 1 wk after completion of the treatment. A third group of irinotecan-treated mice was sacrificed 4 wk after the last application.

  • * p < 0.05; **p < 0.001.